赫迪奥蒂斯 (Hedyotis diffusae herba-Scutellaria Barbata) 是一种草药,通过诱导亡来抑制前列腺癌
Junfeng Qiu1,2, Litong Wu1,2, Zhiming Hong1
1Department of Andrology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, 518033, People's Republic of China.
Scientific reports
|December 17, 2025
概括
这项研究揭示了中国传统医学的作用.
科学领域:
- 瘤学和药理学方面的研究.
- 分子生物学分子生物学
- 传统中国医学 (TCM) 研究研究
背景情况:
- 前列腺癌 (PCa) 是一种常见的男性恶性瘤,对于激素耐药阶段的治疗选择有限.
- 对PCa的TCM药物对Hedyotis Diffusae Herba - Scutellaria Barbatae Herba (HDH-SBH) 的疗效已得到认可,但其潜在的协同机制需要阐明.
- 了解HDH-SBH准的分子通路对于其在癌症治疗中的现代化和应用至关重要.
研究的目的:
- 阐明HDH-SBH抑制前列腺癌进展的分子机制.
- 确定参与亡途径的HDH-SBH的活性成分和核心分子标.
- 为TCM在抗瘤研究中的现代应用提供理论和实验基础.
主要方法:
- 网络药理学被用来预测活性化合物和关键标.
- 用分子对接和分子动力学模拟来评估结合亲和性和稳定性.
- 进行了体外实验,以评估HDH-SBH对PCa细胞增殖,迁移和亡的影响.
主要成果:
- 网络药理学确定了奎尔塞丁,乌尔索酸和阿皮基宁作为向AKT1,BCL2和NFKB的活性成分,这些活性成分在亡途径中得到丰富.
- 分子对接和模拟证实了预测的组件和目标之间的强有力的结合相互作用.
- HDH-SBH显著抑制了PC-3细胞的增殖和迁移,并显著诱导了亡,降低了BCL2和p-65的表达,同时抑制了AKT1酸化.
结论:
- HDH-SBH通过向AKT1/BCL2/NFKB轴来调节亡,有效地抑制前列腺癌的进展.
- 这项研究为使用HDH-SBH作为前列腺癌的潜在治疗剂提供了科学基础.
- 这项研究有助于在瘤学领域现代化传统中医.
相关概念视频
01:27Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K